MEDIFAST INC Stock News

URGENT – New Seats Available (sponsored) Top financial advisors are now accepting new clients for 2024!

Medifast's (MED) Q4 results reflect the impacts of poor customer acquisition. However, it is showing resilience, banking on its strategic focus on medically supported weight loss, indicating potential

Medifast, Inc. (MED) Q4 2023 Earnings Call Transcript

Medifast (MED) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $3.70 per share a year ago.

Every month we look at companies that are delivering not only a solid dividend yield but also showing a trend of growing dividends. Companies that can consistently deliver dividend growth due to risin

Medifast's (MED) fourth-quarter results are likely to reflect the impacts of macroeconomic challenges like inflation, while key growth initiatives like innovation bode well.

We decided to screen our 24/7 Wall St. dividend research database for companies that pay gigantic dividends that investors have likely never heard of.

Medifast's (MED) focus on combining lifestyle coaching with innovative health solutions and targeting diverse markets bode well amid challenges in customer acquisition and high costs.

Dividend growth stocks can provide reliable cash flows and long-term wealth to income investors. In this monthly publication, we screen dividend stocks based on safety, growth, and consistency, which

LifeMD Inc. NASDAQ: LFMD is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing with no health insurance required.

As the markets soar higher following the Federal Reserve's latest decision on interest rates, now may be a great time to jettison any dividend stocks to sell from your portfolio. While stocks overall

High returns on capital typically generate substantial value for long-term investors over extended periods. Businesses yielding high returns often command premium valuations in the market.

Medifast (MED) penetrates the medically supported weight loss market via a collaboration with LifeMD, Inc. (LFMD). The company discontinues quarterly cash dividends.

Medifast partners with LifeMD to offer virtual weight management program with access to GLP-1 drugs. Medifast invests $20 million in LifeMD, with $10 million represented by common stock purchase. Surv

LifeMD Inc (NASDAQ:LFMD) stock traded higher in Wednesday's early trade, up 11% to $8.99, as the health company announced an agreement with Medifast Inc (NYSE:MED), which sees the new partners working